Research Progress of PI3K Signaling Pathway Inhibitors in the Treatment of Pulmonary Fibrosis
10.12259/j.issn.2095-610X.S20250620
- VernacularTitle:PI3K信号通路抑制剂在肺纤维化治疗中的研究进展
- Author:
Yaru SUN
1
;
Guangli SHENG
;
Xuan ZHANG
Author Information
1. 昆明医科大学药学院暨云南省天然药物药理重点实验室/云南省现代生物医药产业学院,云南 昆明 650500
- Keywords:
Pulmonary fibrosis;
PI3K signaling pathway;
Inhibitors;
New drug development
- From:
Journal of Kunming Medical University
2025;46(6):156-162
- CountryChina
- Language:Chinese
-
Abstract:
Pulmonary fibrosis(PF)is a chronic progressive lung disease caused by a variety of etiologies and is also a common outcome of various chronic inflammatory lung diseases.The incidence of pulmonary fibrosis is increasing year by year,with a high mortality rate that seriously threatens the life and health of patients.Although two drugs,pirfenidone and nintedanib,are already on the market for the treatment of pulmonary fibrosis,they can only slow down the progression of the disease but cannot reverse or stop the process of pulmonary fibrosis,and long-term use can produce a variety of adverse reactions.Therefore,it is highly necessary to develop new drugs for pulmonary fibrosis that are more targeted,effective,and well-tolerated by patients.The phosphatidylinositol-3-kinase(PI3K)signaling pathway plays an important role in the pathogenesis of pulmonary fibrosis.Targeted inhibition of the PI3K signaling pathway may be an important direction for the development of new drugs for pulmonary fibrosis.At present,some PI3K signaling pathway inhibitors have shown good effects in preventing and treating pulmonary fibrosis,but most of them are still in the research stage.This article reviews the role of the PI3K signaling pathway in PF,further summarizes promising PI3K pathway inhibitors with PF therapeutic effects,including inhibitors in clinical trials and preclinical studies,and discusses their mechanisms of action and development prospects.
